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Abstract
Invasive fungal infections, predominantly aspergillosis
and candidiasis, are among the most important causes
of  morbidity  and  mortality  in  immunocompromised
patients. Primarily, patients with acute leukemia under-
going  myelosuppressive  chemotherapy  and  allogeneic
stem cell transplant recipients are affected. up to 60%
of patients with invasive aspergillosis, the most com-
mon invasive mycosis among patients with hematologic
malignancies, may still die of their infection, once it has
become  clinically  overt.  the  spectrum  of  antifungal
agents for clinical use now has expanded over the past
ten years and includes the novel class of the echinocan-
dins and two newer generation triazoles with an extend-
ed spectrum of activity against a wide range of fungal
pathogens.  this  review  will  address  pharmacological
characteristics  of  the  two  broad-spectrum  antifungal
azoles, voriconazole and Posaconazole, which are im-
portant for their proper use in clinical practice. 
IntRoductIon
the  incidence  of  invasive  fungal  infections  has  in-
creased over the past decades. this is due to an in-
creased number of at-risk immunocompromised indi-
viduals, such as patients with acute leukemia undergo-
ing myelosuppressive chemotherapy or allogeneic stem
cell transplantation. advances in treatment options for
hematologic  malignancies,  severe  graft-versus-host
disease and serious bacterial infections as well as less
myelosuppressive conditioning regimens for allogeneic
stem cell transplantation have improved clinical out-
come for patients, resulting in an increasing number of
patients  living  with  a  profoundly  compromised  im-
mune system. one of the sequelae is the rise of inva-
sive  fungal  diseases  (Ifd),  which  for  instance  have
doubled  in  the  past  twenty  years  among  allogeneic
stem cell transplant recipients [1]. besides relapse of
leukemia and severe bacterial infection, Ifd remains
the  main  risk  factor  for  poor  outcome  of  leukemia
treatment [2]. up to 60% of patients with invasive as-
pergillosis,  representing  the  most  common  invasive
mycosis  among  patients  with  hematologic  malignan-
cies may still die of their infection, once it has become
clinically overt [3]. this has remained a challenge over
the  past  decades,  while  the  spectrum  of  antifungal
agents  available  for  clinical  use  now  has  expanded
markedly. therapeutic options now include the novel
class of the echinocandins and two newer generation
triazoles with an extended spectrum of activity against
a wide range of fungal pathogens [4]. 
However, many of the new antifungal agents have a
pronounced variability in drug levels based on either
inconsistent absorption or elimination, resulting in a
wide interpatient variability of serum concentrations.
therefore, treatment with the most potent and safe
antifungal agent in the most appropriate dosage is one
of the main challenges for the clinical management of
invasive fungal diseases.
azole antifungal drugs are frequently used for pro-
phylaxis  and  treatment  of  Ifd  [5].  they  exhibit  a
large number of drug-drug interactions. to date, flu-
conazole, itraconazole, voriconazole and posaconazole
are used for prophylaxis and treatment of Ifd in pa-
tients  with  hematologic  malignancies.  they  are  sub-
strates  for  and  inhibitors  of  cytochrome  P450
(cyP450) isoenzymes, as well as inhibitors of mem-
brane transporters such as p-glycoprotein (P-gP). the
antifungal  triazoles  target  ergosterol  biosynthesis  by
inhibiting the fungal cytochrome P450-dependent en-
zyme  lanosterol  14-alpha-demethylase,  causing  cell
membrane defects and cell death or inhibition of cell
growth and replication. the triazoles also inhibit cy-
tochrome P450-dependent enzymes of the functional
respiration  chain.  Itraconazole,  voriconazole  and
posaconazole are active in vitro and in vivo against all
common species of aspergillus. so far, clinically rele-
vant resistance has only rarely been reported, but may
become increasingly important in the future [6].
this review will focus on pharmacology and metab-
olism of voriconazole and posaconazole, the most im-
portant antifungal azoles used in clinical hematology
to  date.  Pharmacokinetic  and  pharmacodynamic  as-
pects, which are clinically relevant for establishing op-
timal dosing regimens against invasive fungal patho  -
gens, will be described with special emphasis on me-
tabolism  and  efficacy  of  the  drugs  in  patients  with
hematologic malignancies and hematopoietic stem cell
transplant recipients (table 1). 
VoRIconazolE
Voriconazole is a second-generation triazole with broad
spectrum  of  antifungal  activity.  the  most  important
therapeutic impact is related to its activity against all
common aspergillus spp. It is considered the first-line
drug for the treatment of invasive aspergillosis[7]. Vori  -
conazole is also approved for treatment of candidemia
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1) Maschmeyer_Umbruchvorlage  23.03.11  12:05  Seite 139in non-neutropenic patients, esophageal candidiasis and
disseminated candidiasis and as first-line therapy for my  -
coses caused by scedosporium and fusarium species. It
is not active against mucormycoses, primarily caused by
Rhizopos, Mucor and absidia species.
PHaRMacoKInEtIcs
Pharmacokinetics  describes  and  predicts  the  time
course  of  drug  concentrations  in  body  fluids.
Voriconazole has non-linear pharmacokinetics and its
dose-response  relationship  exhibits  wide  interpatient
variability. the therapeutic index is narrow, and serum
concentrations are significantly influenced by a broad
range of drug-drug interactions.
Voriconazole  can  be  given  orally  or  as  an  intra-
venous  infusion.  after  oral  administration,  it  is  ab-
sorbed rapidly within 2 hours with an oral bioavailabil-
ity of > 90% [8]. absorption is not affected by gastric
pH, but food delays absorption and reduces bioavail-
ability by 22%. therefore, voriconazole should be tak-
en on an empty stomach [9]. oral voriconazole reach-
es steady-state concentrations after 5-7 days of multi-
ple oral administrations depending on the dosage regi-
men. the time to steady-state can be reduced to 1-2
days by starting with a loading dose. studies showed
non-linear pharmacokinetics with cmax and area un-
der  the  plasma  concentration  time  curve  (auc)  in-
creasing disproportionately with dose for both intra-
venous and oral application of the drug [10]. this in-
dicates  saturation  of  its  metabolism  with  respect  to
dose. the variability in plasma concentration and sys-
temic  dosing  depends  on  genetic  polymorphisms  of
the cytochrome P450 (cyP) isoenzymes, which are in-
volved in the metabolism of voriconazole. 
It is a major substrate for the cyP2c19 isoenzyme
[11]. depending on genetic polymorphisms, resulting
in poor metabolizers and extensive (or rapid) metabo-
lizers, significantly different plasma concentrations are
observed despite identical dosing schedules, and low
trough concentrations have been reported to be asso-
ciated with poor clinical results. this has been docu-
mented in healthy volunteers, in patients with Ifd and
those undergoing hematopoietic stem cell transplanta-
tion [12, 13, 14]. In patients receiving voriconazole for
antifungal prophylaxis, 15% had undetectable concen-
trations and 27% had trough levels below 0.5 mg/l.
only 62% of stem cell transplant recipients had thera-
peutic concentrations between 0.5 and 2 mg/l [15]. In
one  study  examining  the  pharmacokinetics  of
voriconazole in patients after stem cell transplantation,
a wide range of serum concentrations even in intrain-
dividual measurements was observed [13].
Plasma protein binding of voriconazole is 58% and
is  independent  of  plasma  concentration.  cere-
brospinal  fluid  concentrations  of  voriconazole  are
50% of plasma concentrations with even higher con-
centrations obtained in brain tissue. according to the
“free-drug  hypothesis”  of  anti-infective  agents,  the
free-drug concentration must be considered when ex-
ploring the relationship between pharmacokinetic pa-
rameters and in vivo activity [16]. the mean elimina-
tion half-life (t1/2) of voriconazole is about 6 hours
[17]. the mean t1/2 values were greater after multiple
oral  or  intravenous  administrations.  Voriconazole  is
distributed widely into tissues with a volume of distri-
bution of approximately 4.6 l/kg.
since voriconazole is eliminated predominantly by
metabolism, it is likely that its non-linear pharmacoki-
netic profile is probably due to saturation of its me-
tabolism with respect to dose. the variability in plas-
ma  concentrations  and  systemic  exposure  varies  be-
tween patients, depending on the genotype of the he-
patic  cytochrome  P450  (cyP)  enzymes.  the
cyP2c19 isoenzyme, for which voriconazole is an im-
portant substrate, displays frequent genetic polymor-
phisms [18]. Homozygous extensive metabolizers have
a  significantly  lower  exposure  to  voriconazole  than
heterozygous  extensive  or  poor  metabolizers.  Poor
metabolizers  can  have  up  to  4  times  higher  serum
voriconazole concentrations than extensive metaboliz-
ers [19]. However, to date, no dosage adjustments are
recommended with regard to these observations.
overall, the cyP2c19 genotype accounts (in addi-
tion to gender and age) for a large variability in clear-
ance and auc of voriconazole.
dRug IntERactIons
as  voriconazole  is  a  substrate  for  cyP450  isoen-
zymes, multiple drug-drug interactions must be con-
sidered. Particularly, the cyP2c19 genotype and co-
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Table 1. Pharmacokinetic properties of voriconazole and posaconazole.
Property Posaconazole Voriconazole
bioavailability  variable > 95%
(depending on dosage regimen
and food)
Protein binding > 98% 58%
Vd/f (l/kg) 7-25 4.6
tmax (h) 3-6 1-2
Metabolism hepatic: glucuronidation hepatic: cyP2c19, 2c9, 3 a4
t1/2 (h) 15-35 6-24
Elimination route < 1% excreted unchanged in urine hepatic; < 2% excreted
66% excreted unchanged in faeces unchanged in urine
t1/2: elimination half life; tmax: time to reach the maximum plasma concentration; Vd/f: apparent volume of distribution after
oral administration
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may affect voriconazole plasma concentrations (table
2). Voriconazole serum concentrations are significant-
ly reduced by rifampin, rifabutin, phenytoin as well as
carbamazepine  and  long-acting  barbiturates  [19].  at
the same time, plasma concentrations of rifabutin and
phenytoin may be increased resulting in the need of
monitoring their serum levels. the metabolism of oth-
er drugs that are a substrate of cyP metabolic en-
zymes may also be influenced by co-administration of
voriconazole and can result in clinically relevant toxici-
ty if the therapeutic index is small. the list of con-
traindicated co-medication includes sirolimus and er-
got  alkaloids.  dose  monitoring  of  cyclosporine  and
tacrolimus  is  mandatory  when  used  in  combination
with voriconazole, since the latter can increase their
serum  concentrations.  this  is  also  clinically  relevant
for concomitant administration of HMg-coa reduc-
tase inhibitors, sulfonylureas, vinca alkaloids, calcium
channel antagonists and benzodiazepines. 
Voriconazole drug-drug interactions are highly clin-
ically relevant, especially in the treatment of patients
with leukemia and after stem cell transplantation, since
voriconazole  may  interact  with  immunosuppressive
drugs and chemotherapeutic agents.
PHaRMacodynaMIcs
Pharmacodynamics describes the relationship between
drug exposure and outcome (table 3). Voriconazole is
highly effective against most candida spp. including c.
albicans, c. glabrata, c.tropicalis, c.parapsilosis and c.
krusei. Resistance to all available azole antifungals may
occur in strains of c. glabrata and c.krusei [20]. using
macro- and microdilution test methods for the anti-
fungal  susceptibility  of  filamentous  fungi,  voricona-
zole is shown to be highly active against a. fumigatus,
with > 95% of 114 isolates being inhibited at concen-
trations below 0.5 ﾵg/ml [20]. Voriconazole is moder-
ately active against fusarium spp. and scedosporium
spp.,  but  shows  no  relevant  activity  against  zygo  -
mycetes such as Rhizopus, Mucor, Rhizomucor, cun-
ninghamella or absidia [21].
Voriconazole  is  recommended  for  first-line  treat-
ment of invasive aspergillosis in patients with hemato-
logic malignancies and post allogeneic stem cell trans-
plantation [22], since it has been associated with superi-
or response and survival rates in a prospective random-
ized clinical trial comparing the drug with the former
gold standard of amphotericin b deoxycholate [23]. In
a post-hoc analysis, it could be demonstrated, that re-
sponse  and  survival  rates  in  voriconazole-treated  pa-
tients were approximately 20% higher if the antifungal
was started on the basis of a typical radiological sign of
invasive pulmonary aspergillosis, as compared to a de-
ferred  treatment  based  upon  criteria  for  proven  or
probable aspergillosis, as defined by a consensus panel
of the European organization for Research and treat-
ment of cancer and the Mycoses study group of the
national cancer Institute. the place of voriconazole in
the treatment algorithm of empiric therapy for antibi-
otic-refractory neutropenic fever is less well defined. a
prospective study of voriconazole versus liposomal am-
photericin b has shown a very low rateo fbreakthrough
fungal infections in voriconazole recipients in this set-
ting, but failed non-inferiority in the primary composite
endpoint and thereby the approval of vori  conazole for
empirical antifungal therapy in febrile neutropenic pa-
tients. further studies of voriconazole in this clinical
scenario are ongoing. Voriconazole has demonstrated
non-inferiority to fluconazole in prophylaxis of inva-
sive fungal disease in patients after allogeneic stem cell
transplantation in a recently published phase III trial.
when compared to fluconazole 400 mg daily, it reduced
the incidence of invasive aspergillosis, but was non-su-
perior  with  respect  to  disease-free  survival  or  overall
survival  in  this  patient  population  at  the  pre-defined
primary endpoint, i.e. 180 days posttransplant [24].
the efficacy of voriconazole may be related to its
serum  concentration.  while  this  has  never  been
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Table 2. drug interactions with voriconazole.-
Drug Management
Decreases voriconazole interactions
Rifampin contraindicated
Rifabutin contraindicated
Phenytoin monitoring
carbamazepine contraindicated
long-acting barbiturates contraindicated
Ritonavir contraindicated
Efavirenz contraindicated
Increases in concentration by voriconazole
sirolimus contraindicated
Rifabutin contraindicated
Efavirenz contraindiacated
Quinidine contraindicated
tacrolimus monitoring
cyclosporine monitoring
omeprazole reduce dose by half
warfarin monitoring
Methadone reduce dose
Likely increases in concentration by voriconazole
Ergot alkaloids contraindicated
Pimozide contraindicated
sulfonylureas monitoring
HMg-coa reductase inhibitors monitoring
Vinca alkaloids monitoring
calcium channel blockers monitoring
benzodiazepines monitoring
Prednisolone monitoring
HIV protease inhibitors, not indinavir monitoring
Table 3. Pharmacodynamic parameters of voriconazole.
Parameter Characteristics
activity candida: fungistatic
aspergillus: fungicidal
time course of activity candida: time-dependent fungistatic
aspergillus: time-dependent slowly
fungicidal
PafE in vitro candida: no PafE
aspergillus: short PafE
PafE, post-antifungal effect
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spective data suggest that it might be reasonable to
maintain serum voriconazole trough concentrations of
1-2 mg/l to ensure efficacy. the value of a regular and
routine therapeutic drug monitoring, however, is still
debated [25]. 
PosaconazolE
Posaconazole is a lipophilic triazole antifungal agent
with broad-spectrum antifungal activity in vitro and in
vivo against most candida spp., cryptococcus neofor-
mans, aspergillus spp. and several zygomycetes [26]. It
has been developed for prophylaxis and treatment of
fungal infections in immunocompromised individuals
with special consideration of patients with hematolog-
ic malignancies and allogeneic stem cell transplant re-
cipients. Posaconazole is the first antifungal drug that
has demonstrated superior overall survival when used
for  antifungal  prophylaxis  in  patients  with  acute
myeloid leukemia or myelodysplastic syndrome under-
going intensive remission induction chemotherapy.
PHaRMacoKInEtIcs
Posaconazole is available as an oral formulation. Its
pharmacokinetic  profile  is  characterized  by  a  strong
impact of nutrients on its absorption, a long elimina-
tion half-life and, in contrast to voriconazole, an only
minor  metabolism  via  cytochrome  P450  isoenzymes
[27]. the oral absorption of posaconazole is dose-lim-
ited and strongly dependent on the intake of fat-con-
taining food. the time to reach the maximum plasma
concentration is 5-8 hours after administration of a
single dose [28]. the relative bioavailability is signifi-
cantly  increased  by  administration  in  divided  doses.
compared with a single dose, the relative bioavailabili-
ty of posaconazole 800 mg is increased by 98% when
administered in two divided doses every 12 hours, and
by 220% when divided in 4 doses administered at 6-
hours intervals [29]. studies on plasma concentrations
with doses between 50 mg and 800 mg showed a satu-
ration  of  absorption  occurring  above  800  mg.  In
febrile neutropenic patients or those with refractory
invasive fungal disease, there was no further increase
in exposure when the dose was increased from 400 mg
to 600 mg twice daily [30]. 
Posaconazole is highly protein bound (> 98%) and
the  binding  is  concentration-independent.  this
lipophilic drug has a large volume of distribution at
steady-state from approximately 5 l/kg to 25 l/kg.
this suggests extensive extravascular distribution and
penetration into intracellular spaces. steady-state con-
centrations are achieved after 7-10 days resulting in a
mean terminal half-life of around 35 hours [27]. Peak
serum concentration differs significantly between indi-
viduals although differences in renal or hepatic func-
tion, gender, or body mass or surface area differences
do not account for this variation. the reasons for this
interindividual variability remain poorly defined.
Posaconazole is not metabolized to a significant ex-
tent through the cyP enzyme system [31]. the metab-
olism  of  posaconazole  is  mediated  predominantly
through phase-2 biotransformation via uridine diphos-
phate  (udP)-glucuronyltransferase  (ugt)  enzyme
pathways [32]. Posaconazole is also both a substrate
and an inhibitor of p-glycoprotein. the role of poly-
morphisms in genes encoding drug-metabolizing en-
zymes  and  transporters  in  the  pharmacokinetics  of
posaconazole remains to be explored in detail. 
oral  food  intake  increases  the  bioavailability  of
posaconazole [33]. systemic exposure increases by 4-
and 2.6-fold when it is consumed with a high-fat or
non-fat meal, respectively, when compared to fasting
individuals. administering posaconazole with non-fat
food increases its exposure by 164% while inclusion of
fat in a meal further increases posaconazole exposure
by 48%. therefore, posaconazole should be adminis-
tered with a full meal whenever possible, in order to
optimize absorption. In patients who are unable to eat,
e.g. those with severe mucositis after stem cell trans-
plantation, the addition of a liquid nutritional supple-
ment  to  the  administration  of  posaconazole  has
shown efficacy in maintaining sufficient absorption of
the drug [34]. 
for  prophylaxis  of  Ifd  in  patients  with  acute
leukaemia  or  with  gvHd  after  allogeneic  stem  cell
transplantation,  posaconazole  is  administered  at  a
dosage of 600mg daily divided in 3 doses, and for sys-
temic treatment in patients with invasive fungal dis-
ease, 800 mg daily divided in 2 doses with a full meal
or 4 doses without meal.
dRug IntERactIons
the azole drug-drug interactions include competition
for  absorption  and  metabolism,  resulting  in  altered
serum  concentrations  of  posaconazole  itself  or  its
counterpart. as posaconazole undergoes hepatic me-
tabolism via udP glucuronidation and via p-glycopro-
tein efflux, inhibitors or inducers of these clearance
pathways may effect posaconazole serum concentra-
tions. as with other azole antifungals, in vitro studies
have shown that posaconazole is an inhibitor primarily
of cyP3a4. Plasma concentration of drugs predomi-
nantly metabolized by this pathway may be altered by
posaconazole.  a  summary  of  possible  drug  interac-
tions is presented in table 4.
PHaRMacodynaMIcs
Pharmacodynamics refers to the time course and in-
tensity of drug effects on an organism. In these analy-
ses, both the cmax and the auc are important factors
in determining the efficacy of posaconazole in experi-
mental  settings.  Posaconazole  has  shown  activity
against fungal infections including invasive candidiasis,
aspergillosis,  cryptococcosis,  histoplasmosis,  coccid-
ioidomycosis, fusariosis and mucormycosis in numer-
ous preclinical animal and human models [26].
Posaconazole  has  considerable  in  vivo  antifungal
activity, which has been demonstrated in clinical trials.
In clinical practice, it is the drug of first choice for an-
tifungal  prophylaxis  in  patients  with  acute  myeloid
leukemia or myelodysplastic syndrome undergoing in-
tensive remission induction chemotherapy as well as in
patients  with  graft-versus-host  disease  requiring  im-
munosuppressive treatment [22]. 
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graft-versus-host  disease  undergoing  intensive  im-
munosuppressive  therapy  to  antifungal  prophylaxis
with either posaconazole or fluconazole [35]. the inci-
dence of proven or probable invasive fungal infection
was 5.3% versus 9%, thus not reaching statistically sig-
nificant difference. a significant reduction in the num-
ber of cases of invasive aspergillosis in posaconazole
recipients was recorded. while all-cause mortality was
not  reduced,  a  significant  difference  was  observed
with respect to mortality due to invasive fungal infec-
tion  (1%  versus  4%).  the  number  needed  to  treat
(nnt) in order to prevent one invasive fungal infec-
tion with the use of posaconazole versus fluconazole
was 27, whereas the nnt to prevent 1 case of inva-
sive aspergillosis was 22.
cornely et al. studied the role of posaconazole for
prophylaxis of Ifd in patients with acute leukemia or
myelodysplastic  syndrome  undergoing  intensive
chemotherapy in a phase III trial comparing posacona-
zole  with  standard  azole  prophylaxis  in  602  patients
[36].  Patients  were  randomized  to  receive  either
posaconazole or fluconazole or itraconazole, with the
latter selected by local investigators. the mean duration
of  prophylaxis  was  29  days  in  the  posaconazole  pa-
tients and 25 days in the comparator group. Posacona-
zole significantly reduced the incidence of Ifd from
8% to 2%, providing effective prevention of invasive
aspergillosis. for the first time, posaconazole improved
overall survival in this patient population. the nnt to
prevent  1  invasive  fungal  infection  or  1  case  of  as-
pergillosis was 17 for each. the nnt to prevent one
death was 33. Prophylaxis failures were not explained
by  the  variability  in  bioavailability  of  posaconazole.
Plasma  concentrations  of  the  drug  in  patients  with
breakthrough  fungal  infection  were  not  significantly
different from those in the overall patient population. 
these two large randomized trials have established
the role of posaconazole as antifungal of choice for
prophylaxis in these specific patient populations [37].
although there is no head-to-head randomized trial to
date,  posaconazole  appears  superior  to  voriconazole
for prophylaxis of Ifd in patients with acute leukemia
or myelodysplastic syndrome. current evidence-based
guidelines  recommend  its  prophylactic  use  in  this
high-risk  patient  population  undergoing  intensive
myelosuppressive chemotherapy.
Posaconazole has been evaluated as salvage therapy
in  patients  with  refractory  Ifd  [38].  the  partial  or
complete response rate was 60% among patients who
had treatment failure with or were intolerant of other
antifungal drugs. one-fifth of these patients had de-
veloped  breakthrough  infections  with  a  zygomycete
while  receiving  voriconazole.  In  this  patient  cohort,
62% survived and around 40% of deaths were attrib-
uted to fungal infection. In another study in patients
with refractory invasive aspergillosis in 107 patients,
success was obtained in 42% of patients treated with
posaconazole [39]. successful outcome was associated
with higher serum concentrations of posaconazole. In
a quartile analysis of steady-state maximum or average
plasma concentration and response, the response rate
in those 25% patients with lowest concentrations was
24% in opposite to the quartile of patients with high-
est concentrations, in whom a 75% success rate could
be demonstrated [39].
the therapeutic value of serum level monitoring of
posaconazole remains unclear to date. In a subsequent
analysis  of  the  two  above-mentioned  posaconazole
prophylaxis  trials,  posaconazole  concentrations  were
found to significantly correlate with a composite effi-
cacy end point including parameters such as absence
of  premature  discontinuation  of  the  prophylactic
drug, no Ifd and no death. However, the major dri-
ving factor for clinical failure was the administration
of empiric antifungal therapy and not breakthrough
fungal  infections  or  death.  based  upon  these  data,
posaconazole drug monitoring cannot be recommend-
ed by now. 
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Table 4. drug interactions with Posaconazole.
Drug Management
Concentration increased by posaconazole
atazanavir monitoring
cyclosporine reduce dose
lorazepam contraindicated
Midazolam reduce dose
sirolimus contraindicated
tacrolimus reduce dose
Concentration is increased by posaconazole/decreases posacona-
zole concentration
Phenytoin avoid co-administration
Rifabutin avoid co-administration
Decreases posaconazole concentration
cimetidine avoid co-administration
Efavirenz avoid co-administration
Concentration may be increased by posaconazole
alprazolam reduce dose
amiodarone monitoring
astemizole contraindicated
benzodiazepines monitoring
calcium channel blockers monitoring
carbamazepine monitoring
cisapride contraindicated
corticosteroid monitoring
digoxin monitoring
drugs for erectile dysfunction  monitoring
(e.g. sildenafil)
Ergot alkaloids contraindicated
HMg-coa reductase inhibitors monitoring
Irinotecan monitoring
Quinidine contraindicated
sulfonylureas monitoring
terfenadine reduce dose
Vinca alkaloids monitoring
May decrease posaconazole concentrations
famotidine avoid co-administration
omeprazole  avoid co-administration
Ranitidine avoid co-administration
Rifampin monitoring
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